Skip to content

Acute appendicitis and microbiota – etiology and effects of the antimicrobial treatment - MAPPAC

Status
Not yet recruiting
Phases
Phase 4
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2024-519392-26-00
Enrollment
118
Registered
2024-11-26
Start date
Unknown
Completion date
Unknown
Last updated
2024-11-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Complicated acute appendicitis, Uncomplicated acute appendicitis

Brief summary

The endpoint of the study is the microbial outcome, which is defined by evaluating the changes in the gut microbiota species variation. Determining the possible correlation of gut microbiota and complicated appendicitis will be performed by comparing the species variation.

Interventions

DRUGLEVOFLOXACIN
DRUGERTAPENEM
DRUGMETRONIDAZOLE
DRUGMOXIFLOXACIN

Sponsors

Turku University Hospital
Lead SponsorOTHER

Eligibility

Sex/Gender
All
Age
18 Years to 64 Years

Design outcomes

Primary

MeasureTime frame
The endpoint of the study is the microbial outcome, which is defined by evaluating the changes in the gut microbiota species variation. Determining the possible correlation of gut microbiota and complicated appendicitis will be performed by comparing the species variation.

Countries

Finland

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026